Johnson & Johnson has submitted for an additional approval for Tremfya (guselkumab) to treat adults with moderately to severely active Crohn's disease. 21 June 2024
In the USA, the Food and Drug Administration has announced the availability of a draft guidance for industry which could smooth the path for biosimilars develop 21 June 2024
As anticipated following a positive scientific opinion, British pharma major AstraZeneca's Truqap (capivasertib) has been approved by the European Union. 20 June 2024
Chicagoan biopharma giant AbbVie has picked up a new nod for Skyrizi (risankizumab-rzaa), for adults with moderately to severely active ulcerative colitis. 19 June 2024
In the USA, the Federal Trade Commission (FTC) has expressed support for a proposed rule to require the disclosure of all pre-institution patent settlement agre 19 June 2024
In Europe, revised rules for the Clinical Trials Information System (CTIS) are now applicable, offering faster access to clinical trial information in the Europ 18 June 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.